Industry News
Multifunctional Peptides: Novel Direction…
The emerging technologies such as multifunctional peptides, binding peptides, peptide conjugates, oral peptides, long-acting, and delivery systems have greatly contributed to the prosperity o…
Peptide Drug Conjugates (PDCs): Novel Tar…
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics after ADCs, and their core advantages are enhanced cell permeability and improved drug selectivity. In recent y…
Innovative Treatments For Cervical Cancer…
In recent years, the emergence of targeted therapy and immunotherapy has brought new hope to patients with advanced cervical cancer. Currently, two targeted therapies and two immunotherapies …
Overview of Oligonucleotide Therapeutics …
To date, 15 oligonucleotide therapeutics have been approved by the U.S. Food and Drug Administration (FDA) .
Target And Clinical Trial Progress of ADC…
A total of 15 ADC drugs have been approved for hematological malignancies and solid tumors worldwide till now. In addition, there are currently more than 100 ADC candidates are in various sta…
Tetrahydrocurcumin vs Curcumin: What Are …
What is the difference between curcumin and Tetrahydrocurcumin?
Six Biotech Trends For 2023
Recently, the biopharmaceutical industry media BioPharma Dive has released a list of 10 noteworthy clinical trials for the first half of 2023. Here, we overview 6 biotech trends for 2023.
Current Therapies For Non-Small Cell Lung…
Here, we will introduce the current targeted drug therapies and immunotherapies therapies for NSCLC based on official information from the American Cancer Society.
Bystander Effect of Antibody-drug Conjuga…
Summarizing the current preclinical and clinical evidence about bystander effect of ADCs in solid tumors.
2022 FDA Approval & Potencial Blockbu…
FDA approved 37 novel drugs IN 2022, lets find the potencial blockbusters.
sales@huatengusa.com
+86 0731 89916275